Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Study bolsters case that vaccines protect against long-COVID

By Brian Buntz | February 1, 2022

SARS-CoV-2

A scanning electron microscope image shows SARS-CoV-2 (yellow). Credit: NIAID-RML

It may be too soon to know how often the omicron variant is associated with so-called long-COVID, but research from the Leavitt Partners’ COVID-19 Patient Recovery Alliance confirms that vaccination protects against the condition. 

Those who received at least one authorized COVID-19 vaccine dose before diagnosis were between seven and 10 times less likely to report two or more long-COVID-19 symptoms, according to the preprint study conducted before the surge of the delta variant. 

Those who received a vaccine four weeks after diagnosis were four to six times less likely to develop the condition.

There are limits to how well researchers understand the condition given the fuzziness of the definition of long-COVID and the continual emergence of SARS-CoV-2 variants, said Michael A. Simon, principal data scientist at Arcadia, who was involved in the preprint research.

“There’s a lot of information going around and a lot of different kinds of studies,” Simon said. “It’s a little harder to have some cut-and-dried answers.”

Michael Simon

Michael Simon

For one thing, it can be difficult to come up with a universal definition of long-COVID, or post-acute sequelae SARS-CoV-2 infection (PASC). 

In their observational study involving the medical history of 240,648 COVID-19-infected individuals, the COVID-19 Patient Recovery Alliance found that long-COVID is a common phenomenon based on data from the U.S. healthcare system that excluded children. Although symptoms such as fatigue, loss of sense of smell, shortness of breath, vomiting, headaches and so forth are found in the broader population, they are considerably more common in those with prior COVID-19 infections. And those with prior COVID infections were likely to have a constellation of symptoms rather than a single complaint. 

A study recently published in The Lancet reached similar conclusions based on data from a self-reporting app involving 1.266 million people. That study found that having two vaccine doses cut the chances of having symptoms for 28 days or more in half.

“This is an uptick in individuals who are reporting multiple long-term symptoms that have been emblematic of their COVID experience,” Simon said.

Separate studies in Cell and Nature Communications identified a handful of factors that appear to increase the risk of long-COVID.  

The NIH has committed to spending $1.14 billion to investigate long COVID,” which it describes as a “public health priority.”

The Brookings Institution recently concluded long-COVID was a partial explanation of the U.S. labor shortage, accounting for approximately 15% of unfilled jobs. 

It is too early to know if the omicron variant is likely associated with a reduced risk of long-COVID than earlier variants. 

The omicron variant began to drive a surge in infections in late December in much of the world. 

“If you look at the timespan, you need to understand long-COVID, we will only have the data in hand to start thinking about that in the next few weeks,” Simon said. 

A slew of questions related to long-COVID remain unanswered, such as the possibility of the novel coronavirus leading to the onset of chronic conditions, including possible neurological symptoms or worsening of existing neurological issues.

“There are a lot of aspects there that we haven’t had enough of a chance to investigate and that are another level beyond whether individuals are still having fevers or are tired and so on,” Simon said. 

Arcadia plans on conducting further research on long-COVID based on feedback from the COVID-19 Patient Recovery Alliance and other researchers. “We’re going to bring in some more data attributes such as the onset of other chronic conditions,” Simon said. 

The company also plans to look at data before and during the delta wave. “I don’t think we’ll have omicron data yet,” he said, but the company plans on analyzing such data when it becomes available. 

Arcadia plans on analyzing the pandemic’s impact on preventive care. “We asked hypothetically in early 2021 what the negative repercussions of the delay of preventive care would be,” Simon said. Now, those repercussions are beginning to become apparent.

“It’s not just those who are suffering from COVID or long-COVID, but those who made choices during the pandemic who need additional health care,” Simon concluded. 


Filed Under: Infectious Disease
Tagged With: Arcadia, coronavirus, covid-19, COVID-19 vaccine, long-COVID
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

covid-19 vaccine
FDA COVID booster pullback jolts vaccine stocks before gains cool
Coronavirus Covid-19 background - 3d rendering
Pregnancy associated with less long COVID: Researchers call for studies on protective biology
How technology advances are helping scientists unlock the mysteries of zoonotic diseases
Novel coronovirus
Advances in next generation vaccine development for SARS-CoV-2
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE